Immunotherapy Resistance in Pancreatic Cancer

Video

This video examines the role of immunotherapy in pancreatic cancer, highlighting the resistance to novel treatments in this setting and trials attempting to confront this problem.

In this video, Gregory L. Beatty, MD, PhD, of the University of Pennsylvania, discusses the role of immunotherapy in pancreatic cancer, highlighting the resistance to novel treatments in this setting, and how trials are being designed to confront this problem.

Beatty gave a presentation on this subject at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held last month in Chicago.

Recent Videos
Providing easier access to ancillary services for patients with PDAC who live farther away from the treatment center may help them complete the treatment regimen.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Prolonging systemic therapy in patients with gastric or gastroesophageal junction cancers may offer better outcomes than radiation therapy.
Advances in perioperative targeted therapies may enable organ preservation and significantly enhance outcomes for patients with gastric cancers.
Related Content
A Staged Approach Offers Benefits Without OS Detriment in Appendix Cancers

A Staged Approach Offers Benefits Without OS Detriment in Appendix Cancers

Tim Cortese
April 2nd 2025
Article

Muhammad Talwa Waheed, MD, found that resection after appendectomy should be prioritized in the treatment of patients with appendiceal cancer.

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Local Excision After Chemo Achieves Negative Margins in Rectal Cancer

Local Excision After Chemo Achieves Negative Margins in Rectal Cancer

Tim Cortese
March 31st 2025
Article

A phase 2 trial presented at SSO met its primary end point by achieving negative margins in 79% of patients with node-negative rectal cancer.

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

Managing Risks, Planning Treatment, & Making Progress in Pancreatic Cancer

Kelley A. Rone, DNP, RN, AGNP-c
December 2nd 2024
Podcast

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

Next-Generation Test Shows Sensitivity/Specificity in Pancreatic Cancer

Next-Generation Test Shows Sensitivity/Specificity in Pancreatic Cancer

Tim Cortese
March 26th 2025
Article

The blood test showed consistent, strong results in high-risk subgroups such as those with familial history, pancreatic cysts, or diabetes.

Data from the phase 3 CABINET study support the approval of cabozantinib in patients with pancreatic neuroendocrine tumors.

FDA Approves Cabozantinib in Pancreatic/Extra-Pancreatic Neuroendocrine Tumors

Roman Fabbricatore;Ariana Pelosci
March 26th 2025
Article

Data from the phase 3 CABINET study support the approval of cabozantinib in patients with pancreatic and extra-pancreatic neuroendocrine tumors.